XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-based compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation of Share-based Compensation
Total stock-based compensation expense related to all of the Company’s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):
For the Three Months Ended March 31,
20242023
Research and development$1,654 $1,193 
Selling, general and administrative1,943 1,473 
Total stock-based compensation expense$3,597 $2,666 
Schedule of Stock Option Activity Activity for stock options is shown below:
Number of OptionsWeighted Average Exercise Price per ShareWeighted Average Remaining Contractual Term (in years)Aggregate Intrinsic Value (in thousands $)
Outstanding at December 31, 202317,104,505 $3.03 8.3$30,661 
Granted3,970,309 4.38 
Exercised(542,741)2.68 1,233
Canceled/Forfeited(225,111)2.59 
Expired(40,087)5.11 
Outstanding at March 31, 202420,266,875 3.31 8.5$55,369 
Exercisable at March 31, 20245,926,599 $3.66 7.1$16,497 
Schedule of Determination of Fair Value
The estimated grant-date fair value of all the Company’s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:
For the Three Months Ended March 31,
20242023
Expected term (in years)
5.5-6.1
5.3-6.1
Volatility
81%-82%
79%-80%
Risk-free interest rate
3.8%-4.1%
3.4%-4.2%
Dividend Yield—%—%
Schedule of Non-vested Share Activity Activity for restricted shares is shown below:
Number of shares
Unvested as of December 31, 2023374,208 
Vested(105,336)
Unvested as of March 31, 2024268,872 
Activity for restricted stock units is shown below:
Number of SharesWeighted Average Grant Date Fair Value
Unvested as of December 31, 20232,198,334 $1.42 
Granted2,426,855 3.62 
Vested(14,326)2.21 
Forfeitures(61,908)1.56 
Unvested as of March 31, 20244,548,955 $2.59